Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected]
Related Experiment Video
Updated: Sep 20, 2026

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery
Published on: September 30, 2021
Jennifer N Blanchard1, Michael Wohlfeiler, Albert Canas
1Division of General Internal Medicine, University of California, San Diego Medical Center, 92103-8681, USA. jblanchard@ucsd.edu
Abstract:
Pancreatitis occurs in up to 7% of patients infected with human immunodeficiency virus who are treated with standard doses of didanosine. Tenofovir disoproxil fumarate increases the plasma levels of didanosine and, thus, the combination of these agents may increase the risk of pancreatitis. Four cases of pancreatitis that occurred during administration of this drug combination are examined, including 1 that resulted in death.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Antiviral Nucleoside Inhibitors
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Chronic Pancreatitis I: Introduction
Chronic Pancreatitis II: Pathophysiology
Acute Pancreatitis I: Introduction
